| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1016/S1044579X02000937 |
| P698 | PubMed publication ID | 12450736 |
| P50 | author | Fei-Fei Liu | Q38641729 |
| P2860 | cites work | A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4 | Q24322196 |
| EBP2, a human protein that interacts with sequences of the Epstein-Barr virus nuclear antigen 1 important for plasmid maintenance. | Q24517055 | ||
| Proliferation, cell cycle and apoptosis in cancer | Q28189476 | ||
| The kiss of death: promises and failures of death receptors and ligands in cancer therapy | Q28206616 | ||
| Death receptors: signaling and modulation | Q28280897 | ||
| Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5 | Q28303765 | ||
| Apoptosis by death factor | Q28304002 | ||
| Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment | Q29615852 | ||
| Life-or-death decisions by the Bcl-2 protein family. | Q31879227 | ||
| Dissecting the pathways to death | Q33181665 | ||
| Regulation of cell growth and death by Epstein-Barr virus | Q33863072 | ||
| a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer | Q33912833 | ||
| Genetic targeting of adenoviral vectors | Q33996499 | ||
| Epstein-Barr virus infection | Q34004958 | ||
| Three-dimensional intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: the University of California-San Francisco experience. | Q34054134 | ||
| Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials | Q34218132 | ||
| Replication-selective virotherapy for cancer: Biological principles, risk management and future directions | Q34297058 | ||
| Suppression of apoptosis: role in cell growth and neoplasia | Q34309816 | ||
| An adenovirus mutant that replicates selectively in p53-deficient human tumor cells | Q34399844 | ||
| Conditional gene targeting for cancer gene therapy | Q34455157 | ||
| Molecular targeting of gene therapy and radiotherapy | Q34476648 | ||
| P53 gene replacement for cancer--interactions with DNA damaging agents | Q34476655 | ||
| Reovirus therapy of tumors with activated Ras pathway | Q34479740 | ||
| Molecular approaches to chemo-radiotherapy. | Q34501927 | ||
| Myocardial gene therapy | Q34503413 | ||
| Gene therapy of human disease | Q34504197 | ||
| Cancer gene therapy: scientific basis. | Q34511591 | ||
| Breast cancer selective gene expression and therapy mediated by recombinant adenoviruses containing the DF3/MUC1 promoter | Q35768314 | ||
| Development of optimized vectors for gene therapy | Q35965985 | ||
| A cis-acting element from the Epstein-Barr viral genome that permits stable replication of recombinant plasmids in latently infected cells | Q36263086 | ||
| Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity | Q36400613 | ||
| Epstein-Barr virus-coded BHRF1 protein, a viral homologue of Bcl-2, protects human B cells from programmed cell death | Q36535182 | ||
| Identification of EBNA1 amino acid sequences required for the interaction of the functional elements of the Epstein-Barr virus latent origin of DNA replication | Q36648120 | ||
| Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen. | Q37269915 | ||
| Inhibiting tumorigenic potential by restoration of p16 in nasopharyngeal carcinoma | Q38273731 | ||
| Crystal structure of the DNA-binding domain of the Epstein-Barr virus origin-binding protein, EBNA1, bound to DNA. | Q38360539 | ||
| Epstein-Barr virus LMP2A transforms epithelial cells, inhibits cell differentiation, and activates Akt. | Q39585482 | ||
| Development of synthetic promoters for radiation-mediated gene therapy | Q40770533 | ||
| Cisplatin chemotherapy plus adenoviral p53 gene therapy in EBV-positive and -negative nasopharyngeal carcinoma | Q40789611 | ||
| Gene therapy strategies for treating Epstein-Barr virus-associated lymphomas: comparison of two different Epstein-Barr virus-based vectors | Q41034879 | ||
| Downregulation of Fas ligand by shedding | Q41071790 | ||
| Epstein-Barr virus infection and the pathogenesis of nasopharyngeal carcinoma: viral gene expression, tumour cell phenotype, and the role of the lymphoid stroma. | Q41246787 | ||
| Suppression of human nasopharyngeal carcinoma cell growth in nude mice by the wild-type p53 gene | Q41648413 | ||
| Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death | Q41678654 | ||
| Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. | Q41722852 | ||
| Morphological transformation of human keratinocytes expressing the LMP gene of Epstein Barr virus | Q41733704 | ||
| Assessment of p53 expression in nasopharyngeal carcinoma | Q42484432 | ||
| Radiation-induced expression of functional Fas ligand in EBV-positive human nasopharyngeal carcinoma cells. | Q42485739 | ||
| Replicating adenoviral vector-mediated transfer of a heat-inducible double suicide gene for gene therapy | Q43703244 | ||
| Adenovirus-p53 gene therapy in human nasopharyngeal carcinoma xenografts. | Q44568053 | ||
| Observed incidence of tumorigenesis in long-term rodent studies of rAAV vectors. | Q44974380 | ||
| Gene therapy. Safer and virus-free? | Q45734702 | ||
| A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. | Q45739549 | ||
| Absence of nuclear p16 from Epstein-Barr virus-associated undifferentiated nasopharyngeal carcinomas | Q45744905 | ||
| Transcriptional activation of NF-kappa B activity by Epstein-Barr virus (EBV) LMP1 as a selective therapeutic strategy for EBV-associated diseases | Q45752859 | ||
| A strategy for specific targeting of therapeutic agents to tumour cells of virus-associated cancers | Q45763326 | ||
| Use of Epstein-Barr virus nuclear antigen-1 in targeted therapy of EBV-associated neoplasia | Q45767581 | ||
| The effects of combining ionizing radiation and adenoviral p53 therapy in nasopharyngeal carcinoma | Q45856904 | ||
| Cationic liposome-mediated intravenous gene delivery | Q45866771 | ||
| Heat-directed gene targeting of adenoviral vectors to tumor cells | Q45875227 | ||
| Gene therapy. Viral vectors still pack surprises | Q45881684 | ||
| Gene therapy -- promises, problems and prospects | Q45883584 | ||
| Use of EBV-based Vector/HVJ-liposome complex vector for targeted gene therapy of EBV-associated neoplasms | Q45884636 | ||
| Systemic Gene Expression After Intravenous DNA Delivery into Adult Mice | Q46128630 | ||
| EBV persistence in memory B cells in vivo. | Q52037383 | ||
| Expression of bcl-2-, p53, and Ki-67 and outcome of patients with primary nasopharyngeal carcinomas following DNA-damaging treatment. | Q54124546 | ||
| Molecular pathology parameters in human nasopharyngeal carcinoma | Q58876777 | ||
| Establishment and characterization of three transplantable EBV-containing nasopharyngeal carcinomas | Q70061763 | ||
| Infectious poxvirus vectors have capacity for at least 25 000 base pairs of foreign DNA | Q72804855 | ||
| Analysis of the expression of Fas-L in nasopharyngeal carcinoma tissues | Q73380379 | ||
| Retrospective analysis on treating nasopharyngeal carcinoma with accelerated fractionation (6 fractions per week) in comparison with conventional fractionation (5 fractions per week): report on 3-year tumor control and normal tissue toxicity | Q73414262 | ||
| A matter of life and cell death | Q77164675 | ||
| Bcl-2 and LMP1 expression in nasopharyngeal carcinomas | Q77193854 | ||
| P433 | issue | 6 | |
| P921 | main subject | gene therapy | Q213901 |
| P304 | page(s) | 505-515 | |
| P577 | publication date | 2002-12-01 | |
| P1433 | published in | Seminars in Cancer Biology | Q1908668 |
| P1476 | title | Novel gene therapy approach for nasopharyngeal carcinoma | |
| P478 | volume | 12 |
| Q40458621 | Adenovirus-mediated p53 gene therapy in pediatric soft-tissue sarcoma cell lines: sensitization to cisplatin and doxorubicin. |
| Q40050104 | Evaluation of copolymers of N-isopropylacrylamide and 2-dimethyl(aminoethyl)methacrylate in nonviral and adenoviral vectors for gene delivery to nasopharyngeal carcinoma. |
| Q35773862 | Focus on nasopharyngeal carcinoma |
| Q45722385 | Getting oncolytic virus therapies off the ground |
| Q35852258 | Oncolytic viral therapies |
| Q38670423 | Pattern recognition for predictive, preventive, and personalized medicine in cancer. |
| Q94554680 | Radiation-Induced DNMT3B Promotes Radioresistance in Nasopharyngeal Carcinoma through Methylation of p53 and p21 |
| Q41999096 | The expression of p63 is associated with the differential stage in nasopharyngeal carcinoma and EBV infection |
Search more.